TY  - GEN
AU  - Jänne,Pasi A
AU  - Cohen,Roger B
AU  - Laird,A Douglas
AU  - Macé,Sandrine
AU  - Engelman,Jeffrey A
AU  - Ruiz-Soto,Rodrigo
AU  - Rockich,Kevin
AU  - Xu,Jianbo
AU  - Shapiro,Geoffrey I
AU  - Martinez,Pablo
AU  - Felip,Enriqueta
TI  - Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors
SN  - 1556-1380
PY  - 2014///1021
KW  - Adult
KW  - Aged
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Cohort Studies
KW  - ErbB Receptors
KW  - antagonists & inhibitors
KW  - Erlotinib Hydrochloride
KW  - Female
KW  - Follow-Up Studies
KW  - Humans
KW  - Male
KW  - Maximum Tolerated Dose
KW  - Middle Aged
KW  - Neoplasm Staging
KW  - Neoplasms
KW  - drug therapy
KW  - Phosphoinositide-3 Kinase Inhibitors
KW  - Prognosis
KW  - Protein Kinase Inhibitors
KW  - pharmacokinetics
KW  - Quinazolines
KW  - Quinoxalines
KW  - Safety
KW  - Sulfonamides
KW  - Survival Rate
KW  - TOR Serine-Threonine Kinases
KW  - Tissue Distribution
N1  - Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1097/JTO.0000000000000088
ER  -